100例癫痫患者苯妥英钠的血浆蛋白结合情况
Plasma protein binding of phenytoin in 100 epileptic patients.
作者信息
Peterson G M, McLean S, Aldous S, Von Witt R J, Millingen K S
出版信息
Br J Clin Pharmacol. 1982 Aug;14(2):298-300. doi: 10.1111/j.1365-2125.1982.tb01981.x.
Abstract
The plasma protein binding of phenytoin was investigated in 100 epileptic patients, using equilibrium dialysis at 37 degrees C. The unbound fractions of phenytoin in plasma formed a skewed distribution, with a range of 9.7 to 24.7% and a median value of 12.3%. Most (80%) patients appeared to form one group with free phenytoin fractions from 9.7 to 14.5%, while the remainder formed a group with elevated free fractions (greater than 14.5%). Total and unbound plasma concentrations of phenytoin were strongly correlated (r=0.95, P less than 0.0001). There was a weak correlation between increasing age and the unbound phenytoin fraction (r=0.28, P less than 0.01). The results indicate that measurement of the total phenytoin concentration in plasma should usually provide a reliable index of anticonvulsant effect. However, determination of the unbound phenytoin fraction would be beneficial in the management of those patients in whom this fraction may be elevated, due to interacting drugs or biochemical abnormalities.
摘要
采用37℃平衡透析法，对100例癫痫患者的苯妥英血浆蛋白结合情况进行了研究。苯妥英在血浆中的游离分数呈偏态分布，范围为9.7%至24.7%，中位数为12.3%。大多数（80%）患者似乎形成一组，游离苯妥英分数为9.7%至14.5%，而其余患者形成一组游离分数升高（大于14.5%）的组。苯妥英的总血浆浓度与游离血浆浓度密切相关（r=0.95，P<0.0001）。年龄增长与游离苯妥英分数之间存在弱相关性（r=0.28，P<0.01）。结果表明，测定血浆中苯妥英的总浓度通常应能提供抗惊厥作用的可靠指标。然而，对于那些由于相互作用药物或生化异常而可能导致该分数升高的患者，测定游离苯妥英分数将有助于治疗。
相似文献
1
Plasma protein binding of phenytoin in 100 epileptic patients.100例癫痫患者苯妥英钠的血浆蛋白结合情况
Br J Clin Pharmacol. 1982 Aug;14(2):298-300. doi: 10.1111/j.1365-2125.1982.tb01981.x.
2
Two-fold interindividual variation in plasma protein binding of phenytoin in patients with epilepsy.癫痫患者中苯妥英钠血浆蛋白结合的个体间差异达两倍。
Clin Pharmacokinet. 1976 Nov-Dec;1(6):444-52. doi: 10.2165/00003088-197601060-00004.
3
Should we routinely measure free plasma phenytoin concentration?我们应该常规测量游离血浆苯妥英浓度吗？
Br J Clin Pharmacol. 1984 Jan;17(1):99-102. doi: 10.1111/j.1365-2125.1984.tb05007.x.
4
Plasma concentrations of unbound phenytoin in the management of epilepsy.癫痫治疗中游离苯妥英的血浆浓度
Br J Clin Pharmacol. 1984 May;17(5):539-46. doi: 10.1111/j.1365-2125.1984.tb02387.x.
5
Clinical response in epilepsy in relation to total and free serum levels of phenytoin.癫痫的临床反应与苯妥英钠的血清总水平及游离水平的关系。
Ther Drug Monit. 1991 Sep;13(5):415-9. doi: 10.1097/00007691-199109000-00004.
6
Ultrafiltration compared with equilibrium dialysis in the determination of unbound phenytoin in plasma.在血浆中游离苯妥英测定中，超滤法与平衡透析法的比较
Ther Drug Monit. 1985;7(4):461-5. doi: 10.1097/00007691-198512000-00018.
7
Decreased plasma protein binding of phenytoin in patients on valproic acid.丙戊酸治疗的患者中苯妥英的血浆蛋白结合率降低。
Br J Clin Pharmacol. 1979 Dec;8(6):547-52. doi: 10.1111/j.1365-2125.1979.tb01042.x.
8
Use of plasma unbound drug concentrations in adjusting phenytoin doses.利用血浆游离药物浓度调整苯妥英钠剂量。
Ther Drug Monit. 1984;6(2):173-8. doi: 10.1097/00007691-198406000-00007.
9
The EMIT FreeLevel ultrafiltration technique compared with equilibrium dialysis and ultracentrifugation to determine protein binding of phenytoin.将EMIT FreeLevel超滤技术与平衡透析法和超速离心法进行比较，以测定苯妥英的蛋白结合率。
Clin Pharmacokinet. 1984 Jan;9 Suppl 1:61-70. doi: 10.2165/00003088-198400091-00008.
10
Automated determination of free phenytoin in human plasma with on-line equilibrium dialysis and column-switching high-performance liquid chromatography.采用在线平衡透析和柱切换高效液相色谱法自动测定人血浆中的游离苯妥英。
J Chromatogr. 1993 Nov 24;621(2):189-98. doi: 10.1016/0378-4347(93)80095-l.
引用本文的文献
1
Influence of ultrafiltration conditions on the unbound fraction of phenytoin and valproic acid.超滤条件对苯妥英和丙戊酸游离分数的影响。
Eur J Clin Pharmacol. 2025 Sep 9. doi: 10.1007/s00228-025-03918-3.
2
Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug-Drug Interactions of Phenytoin.用于评估苯妥英钠药物相互作用的综合生理药代动力学模型
Pharmaceutics. 2023 Oct 18;15(10):2486. doi: 10.3390/pharmaceutics15102486.
3
Estimation of Free Phenytoin Concentration in Critically Ill Patients with Hypoalbuminemia: Direct-measurement vs Traditional Equations.低白蛋白血症重症患者游离苯妥英浓度的估算：直接测量与传统公式比较
Indian J Crit Care Med. 2022 Jun;26(6):682-687. doi: 10.5005/jp-journals-10071-24235.
4
No Detectable Phenytoin Plasma Levels After Topical Phenytoin Cream Application in Chronic Pain: Inferences for Mechanisms of Action.慢性疼痛患者局部应用苯妥英乳膏后血浆中未检测到苯妥英水平：对作用机制的推断
J Pain Res. 2022 Feb 9;15:377-383. doi: 10.2147/JPR.S345347. eCollection 2022.
5
Single-Blind Placebo-Controlled Response Test with Phenytoin 10% Cream in Neuropathic Pain Patients.苯妥英10%乳膏用于神经性疼痛患者的单盲安慰剂对照反应试验。
Pharmaceuticals (Basel). 2018 Nov 12;11(4):122. doi: 10.3390/ph11040122.
6
Phenytoin Cream for the Treatment for Neuropathic Pain: Case Series.用于治疗神经性疼痛的苯妥英乳膏：病例系列
Pharmaceuticals (Basel). 2018 May 28;11(2):53. doi: 10.3390/ph11020053.
7
A Comparative Analysis of Drug-Induced Hepatotoxicity in Clinically Relevant Situations.临床相关情况下药物性肝毒性的比较分析
PLoS Comput Biol. 2017 Feb 2;13(2):e1005280. doi: 10.1371/journal.pcbi.1005280. eCollection 2017 Feb.
8
Use of Therapeutic Drug Monitoring, Electronic Health Record Data, and Pharmacokinetic Modeling to Determine the Therapeutic Index of Phenytoin and Lamotrigine.利用治疗药物监测、电子健康记录数据和药代动力学模型来确定苯妥英钠和拉莫三嗪的治疗指数。
Ther Drug Monit. 2016 Dec;38(6):728-737. doi: 10.1097/FTD.0000000000000354.
9
Clinical Pharmacology Studies in Critically Ill Children.危重症儿童的临床药理学研究
Pharm Res. 2017 Jan;34(1):7-24. doi: 10.1007/s11095-016-2033-y. Epub 2016 Sep 1.
10
Solvent effects on the structure-property relationship of anticonvulsant hydantoin derivatives: A solvatochromic analysis.溶剂对抗惊厥海因衍生物结构-性质关系的影响：溶剂显色分析
Chem Cent J. 2011 Oct 14;5(1):62. doi: 10.1186/1752-153X-5-62.
本文引用的文献
1
Determination of plasma and cerebrospinal fluid levels of dilantin in the human.人体中苯妥英血浆和脑脊液水平的测定。
Trans Am Neurol Assoc. 1960;85:166-70.
2
5, 5-Diphenylhydantoin (dilantin) blood levels after oral or intravenous dosage in man.人体口服或静脉注射剂量后5,5-二苯基乙内酰脲（苯妥英）的血药浓度。
Acta Pharmacol Toxicol (Copenh). 1960;16:331-46. doi: 10.1111/j.1600-0773.1960.tb01218.x.
3
Altered plasma protein binding of drugs in thyroid disease.甲状腺疾病中药物血浆蛋白结合的改变。
Clin Pharmacokinet. 1981 Jul-Aug;6(4):298-305. doi: 10.2165/00003088-198106040-00004.
4
Binding of drugs to human serum albumin. XIV. The theoretical basis for the interaction between phenytoin and valproate.
Mol Pharmacol. 1980 Sep;18(2):237-42.
5
Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults.血浆蛋白药物结合的年龄差异：对人类胎儿、新生儿和成年人的研究。
Eur J Clin Pharmacol. 1971 Sep;3(4):189-93. doi: 10.1007/BF00565004.
6
Plasma protein binding of diphenylhydantoin in patients with epilepsy. Agreement between the unbound fraction in plasma and the concentration in the cerebrospinal fluid.癫痫患者中苯妥英钠的血浆蛋白结合。血浆中游离分数与脑脊液浓度之间的一致性。
Clin Pharmacol Ther. 1972 Mar-Apr;13(2):196-200. doi: 10.1002/cpt1972132196.
7
Diphenylhydantoin as an anticonvulsant: protein binding and fluctuation of the serum and cerebrospinal fluid levels in forty mentally subnormal epileptics.
J Ment Defic Res. 1969 Dec;13(4):235-44. doi: 10.1111/j.1365-2788.1969.tb01087.x.
8
Diphenylhydantoin concentrations in saliva.唾液中苯妥英钠的浓度。
Arch Neurol. 1974 Jul;31(1):57-9. doi: 10.1001/archneur.1974.00490370083014.
9
Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease.苯妥英钠的血浆蛋白结合。性激素、肾脏和肝脏疾病的影响。
Clin Pharmacol Ther. 1974 Mar;15(3):276-82. doi: 10.1002/cpt1974153276.
10
Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication.血清中游离苯妥英的浓度及其与临床中毒的关系。
Epilepsia. 1973 Jun;14(2):177-84. doi: 10.1111/j.1528-1157.1973.tb03954.x.
Zotero 插件